September 29, 2021
Gilead Sciences said on September 28 that it has filed an application seeking the label expansion of its hepatitis C treatment Epclusa (sofosbuvir + velpatasvir) in Japan to make it available for patients previously untreated with a direct-acting antiviral therapy...read more